Welcome

Covid Boosters Cleared for All Adults as FDA Widens Access (2)

Nov. 19, 2021, 2:36 PM

Covid-19 booster shots from Moderna Inc. and the partnership of Pfizer Inc. and BioNTech SE were cleared by U.S. regulators for all Americans 18 and older, making millions more people eligible for extra protection as concern about a potential winter wave of infections grows.

Adults who received their second dose of the drugmakers’ shots at least six months ago are now eligible to receive a third, according to separate statements from the companies and the the U.S. Food and Drug Administration on Friday.

WATCH: The FDA approves Covid-19 booster shots from Moderna and Pfizer.
Source: AFP

Moderna shares gained as much as 6.2% as of 9:33 a.m. in New York. Shares of Pfizer rose 1.5%, while BioNTech’s American depositary receipts added 3%.

A panel of experts who advise the Centers for Disease Control and Prevention on vaccine policies are expected to review the evidence and make further guidance for administering booster shots at a meeting Friday afternoon.

Booster shots of messenger RNA vaccines have been available for people 65 and over, as well as others who could be at higher risk of severe disease, since mid-September. Under federal guidelines, any of the three authorized shots -- including Johnson & Johnson’s -- can be used as a booster, regardless of the brand of the recipient’s initial vaccination.

Photographer: SOPA Images/LightRocket

The new guidelines will “help to eliminate confusion about who may receive a booster dose and ensure booster doses are available to all who may need one,” Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research said in the agency’s statement.

More than a third of fully vaccinated seniors had received a booster as of Thursday, according to the Centers for Disease Control and Prevention, and 17% of fully vaccinated adults overall have had an additional shot.

State Expansions

Worry that the effectiveness of initial inoculations could fade as the weather cools and more people socialize indoors has driven the most recent push for wider use of boosters. Data presented to U.S. drug regulators by the manufacturers suggested all efficacy has diminished for all three vaccines currently authorized vaccines in the U.S.

Pfizer asked the FDA to expand access to its booster to all adults earlier this month. Pfizer and partner BioNTech said data from a large clinical trial demonstrated a relative vaccine efficacy of 95% for booster recipients when compared with those who didn’t get a booster.

Moderna asked regulators to broaden access to boosters for all adults this week. J&J boosters are currently available to all adults who received the single-shot vaccine at least two months ago.

Numerous states, including Arkansas, California, Colorado, Kansas, Kentucky, Massachusetts and New Mexico, as well as New York City, have already opted to make boosters broadly available. In many of those areas, cases are climbing after a slowdown in the summer’s delta-variant-fueled surge.

Losing Power

At the same time, some scientists say that the evidence the vaccines are losing their protective power is thin and the need for boosters among healthier groups isn’t clear-cut. Some also worry that broader use of boosters could undermine confidence in the initial series. Additionally, allowing younger people to receive third doses of messenger RNA vaccines could increase the risk of myocarditis, a cardiac side effect seen mostly in adolescent males, some fear.

The Biden administration has leaned hard into making boosters broadly available. In August, the White House promised ready availability of supplemental doses before regulators had authorized them, causing some pushback from FDA staff and experts.

The CDC emphasized in October, after first authorizing booster shots for Moderna and J&J vaccine recipients, that it remains focused on getting shots into the arms of people who remain unvaccinated. About 69% of the total U.S. population has received at least one dose of a vaccine through Nov. 18, according to the agency.

(Updates with FDA official’s comment in sixth paragraph.)

--With assistance from Robert Langreth and Riley Griffin.

To contact the reporter on this story:
Fiona Rutherford in New York at frutherford@bloomberg.net

To contact the editors responsible for this story:
Timothy Annett at tannett@bloomberg.net

John Lauerman

© 2021 Bloomberg L.P. All rights reserved. Used with permission.

To read more articles log in.

Learn more about a Bloomberg Law subscription.